Oncolys Biopharma announces that the first patient has been enrolled to the expansion cohort and started protocol treatment, including their first OBP-301 injection for the NRG Oncology sponsored Phase I Clinical Trial for Telomelysin (OBP-301) in combination with chemoradiation in advanced esophageal or gastro-esophageal cancer. This NRG Oncology led study is being conducted via the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). As previously disclosed in the press release on August 10, 2023, the objective of this clinical trial, NRG-GI007, is to evaluate the safety and efficacy of Telomelysin (OBP-301), oncolytic adenoviral immunotherapy, when added to weekly carboplatin, paclitaxel and radiation therapy (ChemoRT), for patients with locally advanced esophageal or gastro-esophageal (GEJ) cancer who are not candidates for surgery.

In the expansion cohort, additional patient enrollment will be conducted to further evaluate the safety of Telomelysin with chemoradiation and obtain preliminary efficacy information. Currently, in Japan, Telomelysin has been confirmed to be effective in combination with radiation therapy for locally advanced esophageal cancer, and Oncolys is planning to submit NDA to Japanese regulatory Authority by the end of 2024.